← Back to Search

M-Tech for Blood Cancers (M-Tech Trial)

N/A
Waitlist Available
Research Sponsored by Kah Poh Loh
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 4-5 months
Awards & highlights

Summary

This trial assesses the feasibility and preliminary efficacy of a care delivery intervention in older patients with hematologic malignancies receiving outpatient chemotherapy.

Who is the study for?
This trial is for people aged 60 or older with certain blood cancers (AML, MDS, MM, DLBCL) who are getting outpatient chemo and can walk a short distance. They shouldn't be planning on stem cell transplants soon, must speak English, have an ECOG status of 0-3 indicating varying levels of activity, and no exercise restrictions from their doctor.Check my eligibility
What is being tested?
The study compares a new tech-supported care method called M-Tech to usual care in managing treatment side effects and improving patient outcomes during chemotherapy. It will also look at healthcare use and biological markers in patients.See study design
What are the potential side effects?
While specific side effects aren't listed for the M-Tech intervention itself since it's technology-based support during chemotherapy, typical chemo side effects may include fatigue, nausea, increased infection risk, hair loss, and potential impact on blood counts.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~4-5 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 4-5 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Difference between experimental and active comparator arms - Clinician-rated non-hematologic treatment-related toxicity
Retention rates
Secondary outcome measures
Difference between experimental and active comparator arms - Functional Status
Difference between experimental and active comparator arms - Healthcare Utilization
Difference between experimental and active comparator arms - Patient-reported treatment-related toxicity
+1 more
Other outcome measures
Difference between experimental and active comparator arms -Inflammatory cytokines

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: M-TechExperimental Treatment1 Intervention
M-Tech involves the use of a mobile app delivery platform to several interventions. The components of M-Tech include: 1) Hybrid in-person and telehealth visits with oncology providers; 2) Disease-specific education videos; 3) Activity level monitoring via a wearable device with promotion of physical activity; 4) Symptom monitoring with provision of self-management strategies, and 5) Medication management.
Group II: Usual CareActive Control1 Intervention
Participants randomized to the usual care arm will receive standard of care.

Find a Location

Who is running the clinical trial?

Kah Poh LohLead Sponsor

Media Library

M-Tech Clinical Trial Eligibility Overview. Trial Name: NCT05153447 — N/A
Cancer Research Study Groups: M-Tech, Usual Care
Cancer Clinical Trial 2023: M-Tech Highlights & Side Effects. Trial Name: NCT05153447 — N/A
M-Tech 2023 Treatment Timeline for Medical Study. Trial Name: NCT05153447 — N/A
~0 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top